Immunitas Therapeutics to Showcase Promising Clinical Findings of IMT-009 at AACR 2026 Annual Meeting Immunitas Therapeutics is set to present significant clinical data regarding its anti-CD161 antibody, IMT-009, at the upcoming AACR 2026 Annual Meeting, highlighting its potential in treating various cancers.

Immunitas Therapeutics to Showcase Promising Clinical Findings of IMT-009 at AACR 2026 Annual Meeting #United_States #San_Diego #Immunitas #IMT-009 #AACR_2026